Bioxytran Inc. (BIXT)
OTCQB OTCQB Primary Summary
Bioxytran's Medical Breakthrough in Fighting All Viruses
Breakthrough was validated in the latest journal article Galectins are essential for viral entry and a new target for drug development Carbohydrates were shown to neutralize viruses Blocking galectins could be the most efficient way to prevent and treat viruses potentially impacting the vaccination and antiviral markets BOSTON, MA / ACCESSWIRE / September 19, 2024 / BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced a medical breakthrough in virology that was validated in a peer-reviewed medical journal article.
Bioxytran Inc. (BIXT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bioxytran Inc. ever had a stock split?
Bioxytran Inc. Profile
| Biotechnology Industry | Healthcare Sector | David Platt CEO | OTCQB Exchange | 09075D102 CUSIP |
| US Country | 2 Employees | - Last Dividend | 9 Mar 2015 Last Split | - IPO Date |
Overview
Bioxytran, Inc. is a clinical stage pharmaceutical company dedicated to innovating the medical landscape by developing, manufacturing, and commercializing therapeutic drugs designed to tackle hypoxia—an ailment where parts of the body are deprived of adequate oxygen supply. Established in 2008 and situated in Needham, Massachusetts, the company directs its expertise towards addressing the complications associated with hypoxic conditions in human health. Through its cutting-edge research and development efforts, Bioxytran, Inc. aims to bring forth novel medical solutions that can significantly improve patient outcomes, particularly for those suffering from conditions arising from or exacerbated by hypoxia.
Products and Services
- BXT-25
This flagship drug candidate by Bioxytran, Inc. represents a pioneering approach to treating hypoxic conditions, particularly in the brain post-stroke, and in wounds where oxygen deficiency could lead to necrosis and hinder healing processes. BXT-25 is an oxygen-carrying small molecule, ingeniously devised from stabilized bovine hemoglobin in conjunction with a co-polymer. This innovative formulation is designed to efficaciously transport oxygen to areas plagued by hypoxia, thereby mitigating the detrimental effects of oxygen deprivation and fostering an environment conducive to healing and recovery.
- ProLectin-Rx
Another promising avenue of Bioxytran's research pertains to the development of ProLectin-Rx, a therapeutic derived from pectin-based polysaccharides. This compound is specifically tailored to identify and inhibit the activity of galectin-1, a type of galectin implicated in a variety of pathological conditions. ProLectin-Rx is being investigated for its potential to treat mild to moderate cases of Covid-19 by blocking the interactions that facilitate the disease's progression. This innovative approach reflects Bioxytran's commitment to leveraging sophisticated biochemical mechanisms for the development of treatments that address pressing global health challenges.
